Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
Primary Purpose
Pars Plana Vitrectomy
Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
HydroLenz Injection
No HydroLenz Injection
Sponsored by
About this trial
This is an interventional prevention trial for Pars Plana Vitrectomy
Eligibility Criteria
Inclusion Criteria:
- Male or female of any race.
- 65 years of age or older.
- Study eye is phakic and scheduled for pars plana vitrectomy (23, 25, or 27 gauge) for epiretinal membrane or vitreomacular traction surgery.
- Willingness and ability to comply with schedule for follow-up visits.
- Subject understands the study requirements and the treatment procedures and provides signed, written informed consent obtained in accordance with the institutional review board (or ethics committee) requirements for this first-in-man early feasibility study.
Exclusion Criteria:
- Aphakic or pseudophakic lens status in either or both eyes.
- History of previous cataract surgery in either eye.
- Evidence of congenital cataract.
Study eye with corneal opacity of one of the following LOCS III grades or condition that would confound the LOCS III grading results:
- Inability to grade opacities in the study eye with LOCS III at the baseline exam;
- Inability to dilate pupil to at least 6.0 mm;
- LOCS III grade ≥ 2 for nuclear opalescence, cortical lens opacities, or posterior subcapsular lens opacities in the study eye at baseline.
- Diabetic retinopathy or macular edema in the study eye.
- Retinal vascular disease or retinopathy in the study eye.
- History of previous intravitreal injections in the study eye.
- History of previous subconjunctival injections in the study eye.
- History of previous radiation in the study eye.
- History of systemic, periocular, inhaled, or chronic topical corticosteroids.
- Previous laser prophylaxis for retinal tear/hole/lattice degeneration in the study eye.
- Previous pneumatic retinopexy or retinal detachment repair in the study eye.
- Previous vitrectomy in the study eye.
- Previous laser treatment anywhere in the study eye (trabecular meshwork, iris, retina, macula).
- Use of silicone oil, air or gas tamponade during the vitrectomy in the study eye prior to injection of the HydroLenz.
- Use of binocular indirect ophthalmoscopy laser during the procedure (endolaser is permitted).
- History of any previous ocular surgery in the study eye.
- Any ocular trauma resulting in lens opacity or subluxation of the lens in the study eye.
- Iatrogenic lens trauma during surgery prior to injection of the HydroLenz.
- Surgical plan for the vitrectomy includes planned glaucoma filtering or tube-shunt procedure or any procedure affecting the lens.
- Female patients who are pregnant or lactating or plan to become pregnant during the course of the study.
- A known sensitivity to study medications for which no alternative medication can be - prescribed.
- Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the HydroLenz treatment or study participation or may confound the outcome of the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Low dose HydroLenz treatment
High dose HydroLenz treatment
Control, i.e., no HydroLenz treatment
Arm Description
Outcomes
Primary Outcome Measures
Evaluation of Changes in Lens Opacities
The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
Evaluation of Changes in Lens Opacities
The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
Changes in BSCVA
Number of eyes losing more than 2 lines of BSCVA
Changes in BSCVA
Number of eyes losing more than 2 lines of BSCVA
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05592912
Brief Title
Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
Official Title
Safety and Preliminary Efficacy of Two Dose Levels of HydroLenz as a Protectant for Vitrectomy-Induced Lens Opacities in Subjects Undergoing Vitrectomy
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2024 (Anticipated)
Primary Completion Date
January 1, 2025 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PromiSight, LLC
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this study is to provide safety data for two different dosages of HydroLenz. Secondary objectives are to provide preliminary data to determine whether HydroLenz has the same effect in humans as it does in the porcine model; to confirm the reliability of methods for evaluating lens opacity; and, to acquire information that can be used to design the pivotal study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pars Plana Vitrectomy
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Low dose HydroLenz treatment
Arm Type
Experimental
Arm Title
High dose HydroLenz treatment
Arm Type
Experimental
Arm Title
Control, i.e., no HydroLenz treatment
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
HydroLenz Injection
Intervention Description
The HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day
Intervention Type
Other
Intervention Name(s)
No HydroLenz Injection
Intervention Description
No HydroLenz injection will be administered at the conclusion of the vitrectomy procedure on the operative day.
Primary Outcome Measure Information:
Title
Evaluation of Changes in Lens Opacities
Description
The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
Time Frame
Baseline and 6 Months
Title
Evaluation of Changes in Lens Opacities
Description
The Lens Opacity Classification System, Version III (LOCS III) and the rate of lens related (cataract) surgery will be used to evaluate the lens opacities.
Time Frame
Baseline and 12 Months
Title
Changes in BSCVA
Description
Number of eyes losing more than 2 lines of BSCVA
Time Frame
Baseline and 6 Months
Title
Changes in BSCVA
Description
Number of eyes losing more than 2 lines of BSCVA
Time Frame
Baseline and 12 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female of any race.
65 years of age or older.
Study eye is phakic and scheduled for pars plana vitrectomy (23, 25, or 27 gauge) for epiretinal membrane or vitreomacular traction surgery.
Willingness and ability to comply with schedule for follow-up visits.
Subject understands the study requirements and the treatment procedures and provides signed, written informed consent obtained in accordance with the institutional review board (or ethics committee) requirements for this first-in-man early feasibility study.
Exclusion Criteria:
Aphakic or pseudophakic lens status in either or both eyes.
History of previous cataract surgery in either eye.
Evidence of congenital cataract.
Study eye with corneal opacity of one of the following LOCS III grades or condition that would confound the LOCS III grading results:
Inability to grade opacities in the study eye with LOCS III at the baseline exam;
Inability to dilate pupil to at least 6.0 mm;
LOCS III grade ≥ 2 for nuclear opalescence, cortical lens opacities, or posterior subcapsular lens opacities in the study eye at baseline.
Diabetic retinopathy or macular edema in the study eye.
Retinal vascular disease or retinopathy in the study eye.
History of previous intravitreal injections in the study eye.
History of previous subconjunctival injections in the study eye.
History of previous radiation in the study eye.
History of systemic, periocular, inhaled, or chronic topical corticosteroids.
Previous laser prophylaxis for retinal tear/hole/lattice degeneration in the study eye.
Previous pneumatic retinopexy or retinal detachment repair in the study eye.
Previous vitrectomy in the study eye.
Previous laser treatment anywhere in the study eye (trabecular meshwork, iris, retina, macula).
Use of silicone oil, air or gas tamponade during the vitrectomy in the study eye prior to injection of the HydroLenz.
Use of binocular indirect ophthalmoscopy laser during the procedure (endolaser is permitted).
History of any previous ocular surgery in the study eye.
Any ocular trauma resulting in lens opacity or subluxation of the lens in the study eye.
Iatrogenic lens trauma during surgery prior to injection of the HydroLenz.
Surgical plan for the vitrectomy includes planned glaucoma filtering or tube-shunt procedure or any procedure affecting the lens.
Female patients who are pregnant or lactating or plan to become pregnant during the course of the study.
A known sensitivity to study medications for which no alternative medication can be - prescribed.
Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the HydroLenz treatment or study participation or may confound the outcome of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jodi S Pitcher
Phone
513-961-8200
Email
jlpitcher@crc-regulatory.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities
We'll reach out to this number within 24 hrs